Broadshore Pharmaceuticals

Broadshore Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing transformative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's lead program, BRS-001, is a novel small molecule inhibitor of p38 alpha MAP kinase, a target known to play a critical role in neuroinflammation and synaptic loss. Founded by industry veterans with extensive experience at Amgen and Bristol Myers Squibb, Broadshore leverages deep expertise in CNS drug development to advance its pipeline. The company has successfully completed a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of BRS-001 in healthy volunteers. Broadshore aims to provide disease-modifying options for patients suffering from cognitive impairment through precision-targeted small molecule interventions. The company operates as a private entity based in Thousand Oaks, California.